Data / Form D filings / Superluminal Medicines, Inc.
Superluminal Medicines, Inc.: Form D filings
Superluminal Medicines, Inc., a biotechnology company in Boston, MA, filed 4 Form D notices with the SEC between 2023 and 2026. The latest, on September 3, 2026, reports $65.5 million sold of a $65.5 million offering to 16 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 15 NECCO ST. LILLY GATEWAY LABS, 4TH FLOOR, Boston, MA, 02110
- Phone
- (301) 525-8752
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2023
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1989478
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | New notice | $65,480,796 | $65,480,796 | 16 | Aug 10, 2026 | sec.gov | |
| Aug 26, 2025 | New notice | $5,000,000 | $5,000,000 | 1 | Aug 14, 2025 | sec.gov | |
| Sep 4, 2024 | New notice | $119,999,984 | $20,041,660 | $99,958,324 | 12 | Aug 21, 2024 | sec.gov |
| Aug 28, 2023 | New notice | $25,679,107 | $25,679,107 | 7 | Mar 3, 2023 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| CONY D'CRUZ | Executive Officer, Director, Promoter | |
| NANDITA SHANGARI | Director | |
| DYLAN MORRIS | Director | |
| DIAMANTIS XYLAS | Director | |
| HARSHA PALADUGU | Director |
Other biotechnology companies in Massachusetts that filed recently
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
- LeanBio Therapeutics, Inc. offering · Oct 22, 2026
- Quiver Holdings Inc. $3 million · Oct 21, 2026
Every Form D from the week of Aug 31, 2026 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Superluminal Medicines, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.